Vistagen Execs Issue New Stock Options, Not Cash Sales, Signal Long‑Term Confidence Amid Volatile Shares
Vistagen insiders issue 75,000 options, signaling long‑term confidence and a potential rebound for the biotech stock.
3 minutes to read
Vistagen Therapeutics Inc
Vistagen Executives Load Up on Zero‑Price Options, Betting Big on Future Growth amid Current Low Valuation
Insider option grants at Vistagen Therapeutics signal executives’ confidence in the stock’s future value, hinting at potential upside amid clinical milestones.
3 minutes to read